No abstract

No abstract

Background Adjuvant chemotherapy trials provide little information on safety in elderly patients because they exclude them or pool their results with those of younger patients. PurposeTo describe the safety of the different adjuvant chemotherapy treatments used in elderly patients with colon cancer. Materials and MethodsRetrospective observational study of colon cancer patients (age >65) diagnosed in 2010 and treated with adjuvant chemotherapy. Each patient was followed from the beginning of the treatment until the end of it. Demographic data, disease stage, antineoplastic agents and treatment-related toxicities were collected from patients’ clinical histories. Results16 patients (5 women, 11 men) were included in the study with a mean age of 75.1 years. 87.5% and 12.5% of patients had stage III and stage II disease, respectively. 6 patients (37.5%) were treated with a combination of 5-fluorouracil and oxaliplatin regimen (FOLFOX), 4 patients (25%) with capecitabine in monotherapy and the remaining 6 patients (37.5%) with a combination of capecitabine and oxaliplatin regimen (XELOX). Adverse events were documented in 100% of patients. 57 adverse reactions were detected, the most frequent toxicities being: neurotoxicity (75% of patients), fatigue and anorexia (68.8%), diarrhoea (37.5%) and thrombocytopenia (37.5%). 54.5% of the undesirable effects were grade 1, 30.9% grade 2 and 14.6% grade 3 toxicities. There were no grade 4 adverse reactions. XELOX was associated with high rates of hand-foot-syndrome (75% of patients) and XELOX and FOLFOX with a high incidence of neurotoxicity (100% and 83.3% respectively). Oncologists had to delay the cycle or reduce the treatment doses in 11 patients (68.8%) and 5 patients (31.3%) had to discontinue the treatment due to the toxicity. Conclusions A high number of adverse reactions were detected, but majority were grade 1–2. The safety profile of drugs studied in our population is in line with that described in the literature in younger patients. No conflict of interest.

No abstract

Background:Patients with immunity mediated inflammatory diseases (IMID) often have clinical manifestations and comorbidity in the field of various medical specialties. A center has been created in our hospital for the comprehensive care of patients with IMID who are being treated with biological therapies (BT) or targeted synthetic molecules (TSM). It is an innovative healthcare model, that incorporate patients into its governance. Physicians, pharmacists and advanced practice nurses (APN), collaborates in consultation or in the day hospital (DH).Objectives:To analyze the activity developed during the first year of operation of the center, with special attention to effectiveness, efficiency, interdisciplinary relationships and patient satisfaction.Methods:Observational analysis with indicators of management and monitoring of patients, care activity, effectiveness, adverse effects, resource consumption and patient satisfaction using the hospital’s own information systems.Results:Center staff during 2019: two admission assistants, one nursing assistant, six nurses, seven part-time doctors and three pharmacists. 1,490 patients were included: 694 (46.6%) Rheumatology (Rheu), 585 (39.3%) Digestive (Dig) and 211 (14.1%) Dermatology (Der) generated 11,363 medical consultations, 14,850 APN consultations and 3,920 treatment sessions in the DH. IV treatment 529/1490 (35.5%) patients (45.0% Reu, 53.9% Dig, 1.1% Der). Patients with rheumatic diseases: rheumatoid arthritis: 339/694, 48.8%; Spondyloarthritis: 226/694, 32.6%; psoriatic arthritis: 117/694, 16.9%; and juvenile idiopathic arthritis: 12/694, 1.7%. 217/1490 (14.6%) patients needed multidisciplinary consultations.Table 1. shows the most relevant indicators and table 2 shows the patient satisfaction survey for 2019.Table 1.relevant indicatorsRHEUDIGDEROn demand consultations 2019 %21.0%34.2%14.3%Teleconsultations 2019 %17.8%41.9%0.0%BT, TSM tapering. %201931.9%0.2%45,5%201818.9%0.2%13.4%BT, TSM intensification. %20195.8%35.2%0.5%20182.6%36.5%0.5%Biosimilars %201943.1%48.5%15.9%201830.4%4.0%12.1%Adherence>90% 2019 %89.4%91.7%86.4%Remission 2019 %47.8%67.3%78.5%hospital admission, any cause pat-years20191.41.70.120181.51.50.04emergency admission, any cause pat-years20192.12.11.620182.12.01.5Table 2.patient satisfaction surveyCategoríaMean and (DS) 1-5General aspects of the center4.3 (0.9)Physicians4.5 (1.1)DH and APN4.5 (1.2)Pharmacy4.6 (0.9)Health proffesional coordinaton4.4 (0.9)Hospital global satisfaction4.3 (0.8)Conclusion:From previous situation there is an increase in interdisciplinary consultations and HD activity maintenance without an increase in human resources. Efficiency (tapering, biosimilars) and patient and staff satisfaction have improved. However, no improvement in adverse effects has been observed, which is an area of improvement. Effectiveness is good, waiting to compare with the previous year. Nutrition and preventive medicine consultations has not been evaluated because have been recently established. Other indicators are being analyzed at the end of the submission deadline.The impact of this pioneering management model, with a holistic approach and incorporating patients into its governance, is difficult to measure until its implementation is completed. Uveitis and psychology consultations and patient school starting in 2020 will improve the quality of IMID patient care, as well as their satisfaction and that of their relatives.Disclosure of Interests:Carlos Gonzalez Consultant of: Gilead, Janssen, Novartis,, Speakers bureau: Abbvie, Celgene, Gilead, Janssen, Novartis, Pfizer, Roche, Luis Alberto Menchén Viso Grant/research support from: Abbvie, Janssen, MSD, Takeda, Consultant of: Abbvie, Janssen, Takeda, MSD, Medtronic, Tillotts, Pfizer, Dr. Falk Pharma, Speakers bureau: Abbvie, Janssen, Takeda, MSD, General Electric, Tillotts, Pfizer, Ferring, General Electric, Fresenius, Ofelia Baniandrés Rodríguez: None declared, Ignacio Marín-Jiménez Consultant of: AbbVie,Chiesi,FAES Farma,Falk-Pharma,Ferring,Gebro Pharma, Hospira,Janssen,MSD,Otsuka Pharmaceutical,Pfizer,Shire,Takeda,Tillots and UCB Pharma, Speakers bureau: AbbVie,Chiesi,FAES Farma,FalkPharma,Ferring,Gebro Pharma,Hospira,Janssen,MSD,Otsuka Pharmaceutical,Pfizer,Shire,Takeda,Tillots and UCB Pharma, Juan Carlos Nieto Speakers bureau: Pfizer, Abbvie, MSD, Novartis, Janssen, Lilly, Nordic Pharma, BMS, Gebro, FAES Farma, Roche, Sanofi, Indalecio Monteagudo: None declared, Arantza Ais Larisgoitia: None declared, Esther Chamorro de Vega: None declared, Elena Lobato Matilla: None declared, Rosa Romero Jiménez: None declared, Ana Herranz Alonso: None declared, Carmen Lobo Rodríguez: None declared, María Prado Simón Moreno: None declared, Jose-Maria Alvaro-Gracia Grant/research support from: Abbvie, Elli-Lilly, MSD, Novartis, Pfizer, Consultant of: Abbvie, BMS, Janssen-Cilag, Elli-Lilly, MSD, Novartis, Pfizer, Sanofi, Tigenix, Roche, UCB, Paid instructor for: Elli-Lilly, Pfizer, Roche, Speakers bureau: Abbvie, BMS, Janssen-Cilag, Elli-Lilly, Gedeon Richter, MSD, Novartis, Pfizer, Sanofi, Tigenix, Roche, UCB, Sonia García de San José: None declared